Recognition of and recent issues in hereditary diffuse gastric cancer

Shinya Sugimoto, Hirokazu Komatsu, Yuichi Morohoshi, Takanori Kanai

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In East Asian countries, gastric cancer incidence is high, but detection rates for germline CDH1 mutations that cause hereditary diffuse gastric cancers (HDGCs) are low. Consequently, screens and genetic testing for HDGC are often considered unimportant. Since the first germline truncating CDH1 mutations in Japanese patients were reported, some HDGC cases have been reported, and some of these involve large germline rearrangements and de novo mutation of CDH1. New methods for mutation detection—such as multiplex ligation-dependent probe amplification, array comparative genomic hybridization, and exome sequencing—have become available, as have new experimental models, including novel gene-knockout mice and gastric organoids. Because of these advances, searches for candidate genes (e.g., CTNNA1, MAP3K6) and our understanding of HDGC pathogenesis have improved in recent years; moreover, there have been substantial changes in the field since the current HDGC consensus guidelines were released. This review focuses on recent issues and advances in the study of HDGC. For example, lobular breast cancer cases and de novo occurrences of DGC are unlikely to meet the existing criteria for genetic testing, but current evidence indicates that some such cases may be good candidates for genetic testing. It is important to recognize that HDGC is a syndrome and that lobular breast cancer can be the first manifestation of this syndrome. CDH1 testing, including analyses of large genomic rearrangements, should be recommended even in countries where few HDGC cases have been reported.

Original languageEnglish
Pages (from-to)831-843
Number of pages13
JournalJournal of Gastroenterology
Volume50
Issue number8
DOIs
Publication statusPublished - 2015 Jun 7

Fingerprint

Stomach Neoplasms
Genetic Testing
Mutation
Organoids
Breast Neoplasms
Exome
Gene Knockout Techniques
Comparative Genomic Hybridization
Germ-Line Mutation
Multiplex Polymerase Chain Reaction
Knockout Mice
Stomach
Theoretical Models
Guidelines
Incidence
Genes

Keywords

  • CDH1
  • E-cadherin
  • Familial cancer
  • Multiplex ligation-dependent probe amplification
  • Signet ring cell

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Recognition of and recent issues in hereditary diffuse gastric cancer. / Sugimoto, Shinya; Komatsu, Hirokazu; Morohoshi, Yuichi; Kanai, Takanori.

In: Journal of Gastroenterology, Vol. 50, No. 8, 07.06.2015, p. 831-843.

Research output: Contribution to journalArticle

Sugimoto, Shinya ; Komatsu, Hirokazu ; Morohoshi, Yuichi ; Kanai, Takanori. / Recognition of and recent issues in hereditary diffuse gastric cancer. In: Journal of Gastroenterology. 2015 ; Vol. 50, No. 8. pp. 831-843.
@article{c15246efb6274538a03107c2904340b5,
title = "Recognition of and recent issues in hereditary diffuse gastric cancer",
abstract = "In East Asian countries, gastric cancer incidence is high, but detection rates for germline CDH1 mutations that cause hereditary diffuse gastric cancers (HDGCs) are low. Consequently, screens and genetic testing for HDGC are often considered unimportant. Since the first germline truncating CDH1 mutations in Japanese patients were reported, some HDGC cases have been reported, and some of these involve large germline rearrangements and de novo mutation of CDH1. New methods for mutation detection—such as multiplex ligation-dependent probe amplification, array comparative genomic hybridization, and exome sequencing—have become available, as have new experimental models, including novel gene-knockout mice and gastric organoids. Because of these advances, searches for candidate genes (e.g., CTNNA1, MAP3K6) and our understanding of HDGC pathogenesis have improved in recent years; moreover, there have been substantial changes in the field since the current HDGC consensus guidelines were released. This review focuses on recent issues and advances in the study of HDGC. For example, lobular breast cancer cases and de novo occurrences of DGC are unlikely to meet the existing criteria for genetic testing, but current evidence indicates that some such cases may be good candidates for genetic testing. It is important to recognize that HDGC is a syndrome and that lobular breast cancer can be the first manifestation of this syndrome. CDH1 testing, including analyses of large genomic rearrangements, should be recommended even in countries where few HDGC cases have been reported.",
keywords = "CDH1, E-cadherin, Familial cancer, Multiplex ligation-dependent probe amplification, Signet ring cell",
author = "Shinya Sugimoto and Hirokazu Komatsu and Yuichi Morohoshi and Takanori Kanai",
year = "2015",
month = "6",
day = "7",
doi = "10.1007/s00535-015-1093-9",
language = "English",
volume = "50",
pages = "831--843",
journal = "Journal of Gastroenterology",
issn = "0944-1174",
publisher = "Springer Japan",
number = "8",

}

TY - JOUR

T1 - Recognition of and recent issues in hereditary diffuse gastric cancer

AU - Sugimoto, Shinya

AU - Komatsu, Hirokazu

AU - Morohoshi, Yuichi

AU - Kanai, Takanori

PY - 2015/6/7

Y1 - 2015/6/7

N2 - In East Asian countries, gastric cancer incidence is high, but detection rates for germline CDH1 mutations that cause hereditary diffuse gastric cancers (HDGCs) are low. Consequently, screens and genetic testing for HDGC are often considered unimportant. Since the first germline truncating CDH1 mutations in Japanese patients were reported, some HDGC cases have been reported, and some of these involve large germline rearrangements and de novo mutation of CDH1. New methods for mutation detection—such as multiplex ligation-dependent probe amplification, array comparative genomic hybridization, and exome sequencing—have become available, as have new experimental models, including novel gene-knockout mice and gastric organoids. Because of these advances, searches for candidate genes (e.g., CTNNA1, MAP3K6) and our understanding of HDGC pathogenesis have improved in recent years; moreover, there have been substantial changes in the field since the current HDGC consensus guidelines were released. This review focuses on recent issues and advances in the study of HDGC. For example, lobular breast cancer cases and de novo occurrences of DGC are unlikely to meet the existing criteria for genetic testing, but current evidence indicates that some such cases may be good candidates for genetic testing. It is important to recognize that HDGC is a syndrome and that lobular breast cancer can be the first manifestation of this syndrome. CDH1 testing, including analyses of large genomic rearrangements, should be recommended even in countries where few HDGC cases have been reported.

AB - In East Asian countries, gastric cancer incidence is high, but detection rates for germline CDH1 mutations that cause hereditary diffuse gastric cancers (HDGCs) are low. Consequently, screens and genetic testing for HDGC are often considered unimportant. Since the first germline truncating CDH1 mutations in Japanese patients were reported, some HDGC cases have been reported, and some of these involve large germline rearrangements and de novo mutation of CDH1. New methods for mutation detection—such as multiplex ligation-dependent probe amplification, array comparative genomic hybridization, and exome sequencing—have become available, as have new experimental models, including novel gene-knockout mice and gastric organoids. Because of these advances, searches for candidate genes (e.g., CTNNA1, MAP3K6) and our understanding of HDGC pathogenesis have improved in recent years; moreover, there have been substantial changes in the field since the current HDGC consensus guidelines were released. This review focuses on recent issues and advances in the study of HDGC. For example, lobular breast cancer cases and de novo occurrences of DGC are unlikely to meet the existing criteria for genetic testing, but current evidence indicates that some such cases may be good candidates for genetic testing. It is important to recognize that HDGC is a syndrome and that lobular breast cancer can be the first manifestation of this syndrome. CDH1 testing, including analyses of large genomic rearrangements, should be recommended even in countries where few HDGC cases have been reported.

KW - CDH1

KW - E-cadherin

KW - Familial cancer

KW - Multiplex ligation-dependent probe amplification

KW - Signet ring cell

UR - http://www.scopus.com/inward/record.url?scp=84938978784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938978784&partnerID=8YFLogxK

U2 - 10.1007/s00535-015-1093-9

DO - 10.1007/s00535-015-1093-9

M3 - Article

VL - 50

SP - 831

EP - 843

JO - Journal of Gastroenterology

JF - Journal of Gastroenterology

SN - 0944-1174

IS - 8

ER -